Table 2. Baseline tumor and treatment characteristics of breast cancer patients by lipid-lowering drug use at recruitment.
| Characteristics | stage I–IV (n = 3189) | stage I–III (n = 3024) | |||
| lipid-loweringdrug use | no lipid-loweringdrug use | lipid-loweringdrug use | no lipid-loweringdrug use | ||
| Patients, n (%) | 305 (9.6) | 2884 (90.4) | 287 (9.5) | 2737 (90.5) | |
| Stage | I | 140 (45.9) | 1311 (45.5) | 138 (48.1) | 1275 (46.6) |
| II | 121 (39.7) | 1181 (41.0) | 117 (40.8) | 1149 (42.0) | |
| III | 32 (10.5) | 316 (11.0) | 32 (11.2) | 313 (11.4) | |
| IV | 12 (3.9) | 76 (2.6) | 0 | 0 | |
| Histological grade | Low | 53 (17.4) | 574 (19.9) | 50 (17.4) | 548 (20.0) |
| Moderate | 166 (54.4) | 1526 (52.9) | 158 (55.1) | 1451 (53.0) | |
| High | 84 (27.5) | 771 (26.7) | 77 (26.8) | 725 (26.5) | |
| Missing | 2 (0.7) | 13 (0.5) | 2 (0.7) | 13 (0.5) | |
| Tumor size | < = 2 cm | 167 (54.8) | 1655 (57.4) | 161 (56.1) | 1602 (58.5) |
| >2–< = 5 cm | 115 (37.7) | 1041 (36.1) | 105 (36.6) | 979 (35.8) | |
| >5 cm | 14 (4.6) | 105 (3.6) | 14 (4.9) | 92 (3.4) | |
| Growth into chest wall/skin | 9 (3.0) | 78 (2.7) | 7 (2.4) | 61 (2.2) | |
| Missing | 0 | 5 (0.2) | 0 | 3 (0.1) | |
| Nodal status, affectedlymph nodes | 0 | 216 (70.8) | 1904 (66.0) | 209 (72.8) | 1834 (67.0) |
| 1–3 | 59 (19.3) | 707 (24.5) | 54 (18.8) | 668 (24.4) | |
| 4–9 | 21 (6.9) | 162 (5.6) | 18 (6.3) | 149 (5.4) | |
| > = 10 | 9 (3.0) | 107 (3.7) | 6 (2.1) | 86 (3.2) | |
| Missing | 0 (0.0) | 4 (0.1) | 0 | 0 | |
| Metastases at recruitment | No metastases | 293 (96.1) | 2808 (97.4) | 287 (100.0) | 2737 (100.0) |
| Metastases | 12 (3.9) | 76 (2.6) | 0 | 0 | |
| ER/PR status | ER+PR+ | 193 (63.3) | 1857 (64.4) | 182 (63.4) | 1765 (64.5) |
| ER+PR−/ER−PR+ | 61 (20.0) | 539 (18.7) | 57 (19.9) | 505 (18.5) | |
| ER−PR− | 50 (16.4) | 488 (16.9) | 47 (16.4) | 467 (17.1) | |
| Missing | 1 (0.3) | 0 | 1 (0.4) | 0 | |
| HER2 status | HER2+ | 54 (17.7) | 520 (18.0) | 48 (16.7) | 489 (17.9) |
| HER2− | 219 (71.8) | 2099 (72.8) | 207 (72.1) | 1991 (72.7) | |
| Missing | 32 (10.5) | 265 (9.2) | 32 (11.2) | 257 (9.4) | |
| Type of surgery | Ablatio | 81 (26.6) | 850 (29.5) | 75 (26.1) | 776 (28.4) |
| Breast conserving | 222 (72.8) | 2018 (70.0) | 210 (73.2) | 1946 (71.1) | |
| Missing | 2 (0.7) | 16 (0.6) | 2 (0.7) | 15 (0.6) | |
| Chemotherapy | No | 173 (56.7) | 1377 (47.8) | 163 (56.8) | 1310 (47.9) |
| Yes | 127 (41.6) | 1457 (50.5) | 121 (42.2) | 1386 (50.6) | |
| Missing | 5 (1.6) | 50 (1.7) | 3 (1.1) | 41 (1.5) | |
| Radiotherapy | No | 54 (17.7) | 572 (19.8) | 44 (15.3) | 499 (18.2) |
| Yes | 245 (80.3) | 2276 (78.9) | 237 (82.6) | 2207 (80.6) | |
| Missing | 6 (2.0) | 36 (1.3) | 6 (2.1) | 31 (1.1) | |
| Endocrine therapy | No tamoxifen and aromatase inhibitor use | 54 (17.7) | 454 (15.7) | 53 (18.5) | 442 (16.2) |
| Ever tamoxifen or aromatase inhibitor use | 239 (78.4) | 2270 (78.7) | 225 (78.4) | 2150 (78.6) | |
| Missing | 12 (3.9) | 160 (5.6) | 9 (3.1) | 145 (5.3) | |
| Mode of detection | self-discovered (palpation, secretion, doctor visitbecause of pain) | 161 (52.8) | 1572 (54.5) | 149 (51.9) | 1477 (54.0) |
| discovered by routine investigation, mammography, ultrasound | 142 (46.6) | 1303 (45.2) | 136 (47.4) | 1252 (45.7) | |
| Missing | 2 (0.7) | 9 (0.3) | 2 (0.7) | 8 (0.3) | |